Antimicrobial Resistance & Healthcare-Associated Infection Unit, HPA-Colindale, London NW9 5EQ, UK.
J Antimicrob Chemother. 2013 Jul;68(7):1601-8. doi: 10.1093/jac/dkt050. Epub 2013 Feb 28.
We investigated the activity of BAL30072, a dihydroxypyridone monosulfactam, against carbapenem-resistant Enterobacteriaceae and non-fermenters (i) alone, (ii) combined with BAL29880 (to inhibit AmpC) and/or clavulanate [to inhibit extended-spectrum β-lactamases (ESBLs)] and (iii) combined 1:1 with meropenem.
Isolates were from multiple UK hospitals. MICs were determined by CLSI agar dilution. Carbapenemases were identified by PCR and sequencing.
BAL30072 inhibited 69% of the carbapenem-resistant Enterobacteriaceae at ≤4 mg/L, including 60%-87% with OXA-48, IMP, NDM and VIM enzymes or combinations of impermeability with AmpC or ESBL, and 40% with KPC enzymes. The proportions susceptible exceeded 90% for BAL30072+BAL29880+clavulanate, except for isolates with KPC carbapenemases, where members of the international sequence type (ST) 258 Klebsiella pneumoniae clone remained resistant. At 4 mg/L, BAL30072 was active against all OprD-deficient Pseudomonas aeruginosa, against 8/12 with efflux-type β-lactam resistance and 19/25 with metallo-carbapenemases; these proportions were little increased if inhibitors were added. Most Acinetobacter baumannii with OXA or NDM carbapenemases were susceptible to BAL30072 alone at ≤4 mg/L, but those with OXA-58 were resistant, probably for reasons other than their β-lactamase. Addition of meropenem to BAL30072 increased activity against some individual isolates, but with little clear relationship to the resistance mechanism, except for consistent potentiation against OprD-deficient P. aeruginosa.
BAL30072 had good activity against many diverse carbapenem resistance types. Adding clavulanate and/or BAL29880 extended activity against carbapenem-resistant Enterobacteriaceae, but not non-fermenters. Adding meropenem resulted in small increases in activity against individual isolates. Resistance remained common in the K. pneumoniae ST258 KPC clone, even with both inhibitors or meropenem added.
研究二羟吡啶单磺酰胺 BAL30072 单独使用、与 BAL29880(抑制 AmpC)和/或克拉维酸(抑制广谱β-内酰胺酶(ESBLs))联合使用以及与美罗培南以 1:1 比例联合使用时对碳青霉烯类耐药肠杆菌科和非发酵菌的活性。
分离株来自英国多家医院。采用 CLSI 琼脂稀释法测定 MIC。通过 PCR 和测序鉴定碳青霉烯酶。
BAL30072 在 ≤4mg/L 时抑制 69%的碳青霉烯类耐药肠杆菌科,其中 OXA-48、IMP、NDM 和 VIM 酶或其与通透性降低加 AmpC 或 ESBL 的组合的抑制率为 60%-87%,对 KPC 酶的抑制率为 40%。BAL30072+BAL29880+克拉维酸的敏感率超过 90%,除了携带 KPC 碳青霉烯酶的分离株,国际序列型(ST)258 肺炎克雷伯菌克隆的成员仍存在耐药性。在 4mg/L 时,BAL30072 对所有 OprD 缺失铜绿假单胞菌均有活性,对 12 株中有 8 株具有外排型β-内酰胺耐药性的菌株和 25 株中有 19 株具有金属碳青霉烯酶的菌株的活性略有增加,如果加入抑制剂则活性增加较小。大多数携带 OXA 或 NDM 碳青霉烯酶的鲍曼不动杆菌在 ≤4mg/L 时单独使用 BAL30072 即可被抑制,但对 OXA-58 的抑制作用则耐药,可能不是由于其β-内酰胺酶。美罗培南与 BAL30072 联合使用可增加对一些分离株的活性,但与耐药机制没有明显关系,除了对 OprD 缺失铜绿假单胞菌的一致增效作用外。
BAL30072 对多种不同的碳青霉烯类耐药类型具有良好的活性。添加克拉维酸和/或 BAL29880 可扩大对碳青霉烯类耐药肠杆菌科的作用,但对非发酵菌无效。加入美罗培南可使个别分离株的活性略有增加。即使同时加入两种抑制剂或美罗培南,K. pneumoniae ST258 KPC 克隆中的 KPC 仍普遍存在耐药性。